Version 2 of the Cochrane risk-of-bias tool for randomized controlled trials. by Solima Sabeel (9545738)

Subjects:

Analysis of randomized controlled trials stratified based on treatment duration. by Solima Sabeel (9545738)

Subjects:

Funnel plots of studies included in the meta-analysis assessing by Solima Sabeel (9545738)

Subjects:

Summary of non-randomized studies. by Solima Sabeel (9545738)

Subjects:

PRISMA flow diagram of the systematic literature search process. by Solima Sabeel (9545738)

Subjects:

Table 1_Organic fertilizer in combination with zeolite enhanced maize yield with lower greenhouse gas emissions in sandy loam soil in North China.docx by Xuexia Wang (3701098)

“…Compared with SF, the total global warming potential (GWP) was significantly lower by 4.78% in ZOF in 2023, the greenhouse gas intensity (GHGI) was significantly lower over the 3 years of trials by 6.45–15.31% and 14.16–21.06% in treatments ZSF and ZOF, respectively, and was significantly lower by 10.53–13.13% in OF in 2022 and 2023. …”

Participant characteristics. by Ronald Kusolo (13200268)

“…The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”

Fig 1 - Fusing multisensory signals across channels and time by Swathi Anil (17382903)

Uganda 2023 NCD risk factor STEPS survey data. by Ronald Kusolo (13200268)

“…The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”

Uganda 2014 NCD risk factor STEPS survey data. by Ronald Kusolo (13200268)

“…The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”

Image1_The immunological and prognostic significance of the diabetes mellitus-related gene WFS1 in endometrial cancer.tif by Wenzhe Li (815057)

“…</p>Results<p>The EC group had significantly lower WFS1 expression, with an AUC of 0.857 for the ROC diagnostic curve. …”

Table2_The immunological and prognostic significance of the diabetes mellitus-related gene WFS1 in endometrial cancer.xlsx by Wenzhe Li (815057)

“…</p>Results<p>The EC group had significantly lower WFS1 expression, with an AUC of 0.857 for the ROC diagnostic curve. …”

Table3_The immunological and prognostic significance of the diabetes mellitus-related gene WFS1 in endometrial cancer.docx by Wenzhe Li (815057)

“…</p>Results<p>The EC group had significantly lower WFS1 expression, with an AUC of 0.857 for the ROC diagnostic curve. …”

Table1_The immunological and prognostic significance of the diabetes mellitus-related gene WFS1 in endometrial cancer.xlsx by Wenzhe Li (815057)

“…</p>Results<p>The EC group had significantly lower WFS1 expression, with an AUC of 0.857 for the ROC diagnostic curve. …”

CFSE staining of CD8+ T-cells for proliferation assessment. by Eiman Abdo (20642254)

Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”